TXMD vs DBVT vs ABBV vs ALKS

For growth investors, TherapeuticsMD, Inc.

(TXMD) is the stronger pick with 35. 3% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

5x versus AbbVie Inc. at 85. 0x.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +99. 6%, compared to -96. 2% for TherapeuticsMD, Inc. (TXMD). Over 10 years, the gap is even starker: ABBV returned +293. 8% versus TXMD's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 357% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 26% for TherapeuticsMD, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TherapeuticsMD, Inc.

(TXMD) is pulling ahead at 35. 3% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: TherapeuticsMD, Inc. grew EPS 74. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -123. 9% for TherapeuticsMD, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -270. 3% for TXMD. At the gross margin level — before operating expenses — TXMD leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 134.

8% to $46. 33.

In this comparison, ABBV (3.

3% yield) pays a dividend. TXMD, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 3% yield, +293. 8% 10Y return). Both have compounded well over 10 years (ABBV: +293. 8%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TXMD is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ABBV is a large-cap income-oriented stock; ALKS is a small-cap quality compounder stock. ABBV pays a dividend while TXMD, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.